4.8 Article

Rapid and simultaneous visual screening of SARS-CoV-2 and influenza virufses with customized isothermal amplification integrated lateral flow strip

期刊

BIOSENSORS & BIOELECTRONICS
卷 197, 期 -, 页码 -

出版社

ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2021.113771

关键词

SARS-CoV-2; Influenza virus; Recombinase polymerase amplification; Lateral flow strip; Simultaneous identification

资金

  1. NSFC [32172295, 21804028]
  2. Ministry of Science and Technology of China [2018YFC1603606]
  3. key R&D program of Anhui [202004a07020002, 202004a07020004, 201904d07020016]
  4. Anhui Provincial NSF [1908085QC121]
  5. China Postdoctoral Science Foundation [2019M652167]
  6. Fund of State Key Lab of Chemo/Bio-sensing and Chemometrics (Hunan University)
  7. Young and Middle-aged Leading Scientists, Engineers and Innovators of the XPCC [2019CB017, CARS-48]
  8. China Agriculture Research System-48 [CARS-48]

向作者/读者索取更多资源

This work introduces a new detection technology that can simultaneously test for SARS-CoV-2 and influenza viruses, with advantages such as speed, high sensitivity, no cross-reactivity, and false positives. Its clinical application demonstrates high accuracy, and this portable device is expected to meet the global healthcare system's need for online monitoring of serious infectious diseases.
Due to the similar clinical symptoms of influenza (Flu) and coronavirus disease 2019 (COVID-19), there is a looming infection threat of concurrent Flu viruses and severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). In this work, we introduce a customized isothermal amplification integrated lateral flow strip (LFS) that is capable performing duplex reverse transcription-recombinase polymerase amplification (RT-RPA) and colorimetric LFS in a sequential manner. With customized amplification primer sets targeted to SARS-CoV-2 (opening reading frame 1a/b and nucleoprotein genes) and Flu viruses (Flu A and Flu B), the platform allows the rapid and simultaneous visual screening of SARS-CoV-2 and Flu viruses (Flu A and Flu B) without cross reactivity, false positives, and false negatives. Moreover, it maximally eases the detection, reduces the detection time (1 h), and improves the assay performance to detect as low as 10 copies of the viral RNA. Its clinical application is powerfully demonstrated with 100% accuracy for evaluating 15 SARS-CoV-2-positive clinical samples, 10 Flu viruses-positive clinical samples, and 5 negative clinical samples, which were pre-confirmed by standard qRT-PCR. We envision this portable device can meet the increasing need of online monitoring the serious infectious diseases that substantially affects health care systems worldwide.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据